AVTX vs BBOT: fair value comparison
Avalo Therapeutics, Inc. and BridgeBio Oncology Therapeutics, Inc. · Updated 2026-10-19
AVTX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. BBOT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, AVTX currently ranks higher by quality score.
| AVTX | BBOT | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $11.27 | $2.82 |
| 12-month range | $11.27–$22.87 | $2.82–$13.73 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #222 of 301 Healthcare | #223 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | — |
| Revenue growth | Declining | — |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: AVTX fair value analysis · BBOT fair value analysis